At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Aug 10, 2026 at 16:01 ET
Septerna reported Q2 2026 financial results highlighting a net loss of $13.0M (EPS -$0.29) vs consensus of -$0.48, a 39.6% beat. Pipeline progress was steady: SEP-479 Phase 1 PK supports once-daily dosing with SAD/MAD data expected Q1 2027; SEP-631 Phase 1 data positive; TSHR NAM advancing toward candidate selection. Cash of $516.5M funds operations into 2029. Collaboration revenue of $26.7M from Novo Nordisk drove the beat, but as a clinical-stage biotech this is non-core milestone/amortization revenue, the EPS surprise is mechanical, not growth-driven.
- Net loss was $13.0M for Q2 2026 vs $24.8M in Q2 2025; EPS -$0.29 vs consensus -$0.48 (beat).
- Revenue of $26.7M from Novo Nordisk collaboration (amortization of $14.6M upfront + $0.9M milestones + $11.2M research services).
- SEP-479 Phase 1 ongoing; observed half-life ~3–4 days supports once-daily dosing; SAD/MAD data expected Q1 2027.
- SEP-631 Phase 1 results reported March 2026: well-tolerated, once-daily PK, robust skin wheal suppression; evaluating Phase 2 strategies.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access